Paul Newell

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

Yehuda Carmeli, J. Armstrong, Peter J. Laud et al. · The Lancet Infectious Diseases · 2016 · 409 citations

Life Sciences, Infectious Diseases, Microbiology +17

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

John E. Mazuski, Leanne B. Gasink, J. Armstrong et al. · Clinical Infectious Diseases · 2016 · 385 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

Florian Wagenlehner, Jack D. Sobel, Paul Newell et al. · Clinical Infectious Diseases · 2016 · 352 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +17

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme

Gregory G. Stone, Paul Newell, Leanne B. Gasink et al. · Journal of Antimicrobial Chemotherapy · 2018 · 77 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial

John S. Bradley, Emmanuel Roilides, Helen Broadhurst et al. · The Pediatric Infectious Disease Journal · 2019 · 71 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +17